Axon Enterprise, Inc $AXON Shares Acquired by Ethic Inc.

Ethic Inc. increased its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 9,571.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 618,108 shares of the biotechnology company’s stock after purchasing an additional 611,717 shares during the quarter. Axon Enterprise makes up approximately 2.9% of Ethic Inc.’s portfolio, making the stock its 4th largest position. Ethic Inc. owned about 0.76% of Axon Enterprise worth $261,163,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Keel Point LLC lifted its position in Axon Enterprise by 4.4% in the 1st quarter. Keel Point LLC now owns 599 shares of the biotechnology company’s stock worth $254,000 after buying an additional 25 shares in the last quarter. Bridgewater Advisors Inc. boosted its stake in shares of Axon Enterprise by 4.4% during the 2nd quarter. Bridgewater Advisors Inc. now owns 616 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 26 shares during the period. Pinnacle Wealth Planning Services Inc. grew its holdings in shares of Axon Enterprise by 7.8% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 361 shares of the biotechnology company’s stock valued at $153,000 after acquiring an additional 26 shares in the last quarter. 44 Wealth Management LLC grew its holdings in shares of Axon Enterprise by 6.0% during the 1st quarter. 44 Wealth Management LLC now owns 530 shares of the biotechnology company’s stock valued at $225,000 after acquiring an additional 30 shares in the last quarter. Finally, Owl Creek Wealth Partners LLC grew its holdings in shares of Axon Enterprise by 84.8% during the 2nd quarter. Owl Creek Wealth Partners LLC now owns 85 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 39 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on AXON. UBS Group increased their price objective on Axon Enterprise from $440.00 to $600.00 and gave the stock a “neutral” rating in a report on Thursday, August 6th. Raymond James Financial set a $675.00 price objective on Axon Enterprise in a research report on Thursday, October 15th. The Goldman Sachs Group lowered their target price on Axon Enterprise from $715.00 to $675.00 and set a “buy” rating on the stock in a research note on Monday, September 21st. TD Cowen dropped their target price on Axon Enterprise from $825.00 to $800.00 and set a “buy” rating on the stock in a research report on Monday, October 26th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research report on Tuesday. Thirteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $631.35.

Axon Enterprise Stock Down 18.2%

Axon Enterprise stock opened at $313.00 on Friday. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. Axon Enterprise, Inc has a 1-year low of $307.00 and a 1-year high of $665.07. The firm’s fifty day simple moving average is $441.53 and its 200-day simple moving average is $475.20. The company has a market capitalization of $25.43 billion, a P/E ratio of 100.32, a P/E/G ratio of 5.95 and a beta of 1.48.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). The business had revenue of $908.55 million during the quarter, compared to the consensus estimate of $934.33 million. Axon Enterprise had a return on equity of 3.95% and a net margin of 7.56%. The company’s revenue for the quarter was up 27.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.17 earnings per share. Sell-side analysts forecast that Axon Enterprise, Inc will post 2.10 earnings per share for the current fiscal year.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 16,775 shares of the business’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $574.43, for a total value of $9,636,063.25. Following the completion of the sale, the president owned 296,974 shares of the company’s stock, valued at $170,590,774.82. The trade was a 5.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey Kunins sold 9,605 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $626.70, for a total value of $6,019,453.50. Following the sale, the insider owned 97,761 shares of the company’s stock, valued at approximately $61,266,818.70. This trade represents a 8.95% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 37,397 shares of company stock valued at $21,234,034 in the last three months. 4.20% of the stock is currently owned by corporate insiders.

About Axon Enterprise

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.